Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases
Antimicrobial Agents and Chemotherapy · 04.09.2024 · 68 (9)
DOI: 10.1128/aac.00272-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.09.2024. Verfasst von Caitlyn M Rotondo und 1 weiteren Autor:innen. Beteiligte Einrichtung: David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Azabicyclo Compounds, beta-Lactamases, Anti-Bacterial Agents, Microbial Sensitivity Tests. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR).
Abstract (Originalsprache)
The effectiveness of β-lactam antibiotics is increasingly threatened by resistant bacteria that harbor hydrolytic β-lactamase enzymes. Depending on the class of β-lactamase present, β-lactam hydrolysis can occur through one of two general molecular mechanisms. Metallo-β-lactamases (MBLs) require active site Zn 2+ ions, whereas serine-β-lactamases (SBLs) deploy a catalytic serine residue. The result in both cases is drug inactivation via the opening of the β-lactam warhead of the antibiotic. MBLs confer resistance to most β-lactams and are non-susceptible to SBL inhibitors, including recently approved diazabicyclooctanes, such as avibactam; consequently, these enzymes represent a growing threat to public health. Aspergillomarasmine A (AMA), a fungal natural product, can rescue the activity of the β-lactam antibiotic meropenem against MBL-expressing bacterial strains. However, the effectiveness of this β-lactam/β-lactamase inhibitor combination against bacteria producing multiple β-lactamases remains unknown. We systematically investigated the efficacy of AMA/meropenem combination therapy with and without avibactam against 10 Escherichia coli and 10 Klebsiella pneumoniae laboratory strains tandemly expressing single MBL and SBL enzymes. Cell-based assays demonstrated that laboratory strains producing NDM-1 and KPC-2 carbapenemases were resistant to the AMA/meropenem combination but became drug-susceptible upon adding avibactam. We also probed these combinations against 30 clinical isolates expressing multiple β-lactamases. E. coli , Enterobacter cloacae, and K. pneumoniae clinical isolates were more susceptible to AMA, avibactam, and meropenem than Pseudomonas aeruginosa and Acinetobacter baumannii isolates. Overall, the results demonstrate that a triple combination of AMA/avibactam/meropenem has potential for empirical treatment of infections caused by multiple β-lactamase-producing bacteria, especially Enterobacterales.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, Ontario, Canada.
- M.G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Caitlyn M Rotondo, Gerard D Wright
Förderung
- Canadian Government | Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Rotondo, C. M., & Wright, G. D. (2024). Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases. Antimicrobial Agents and Chemotherapy, 68(9). https://doi.org/10.1128/aac.00272-24
Vancouver
Rotondo CM, Wright GD. Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases. Antimicrobial Agents and Chemotherapy. 2024;68(9). doi:10.1128/aac.00272-24
BibTeX
@article{Rotondo2024,
author = {Rotondo, Caitlyn M and Wright, Gerard D},
title = {Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {9},
doi = {10.1128/aac.00272-24}
}
EUVIMED